Sutro Biopharma Q2 EPS $(0.59) Beats $(0.79) Estimate, Sales $25.70M Beat $21.02M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sutro Biopharma (NASDAQ:STRO) reported better-than-expected Q2 results with EPS of $(0.59) beating the estimate of $(0.79) and sales of $25.70M surpassing the $21.02M estimate. This marks a significant improvement from the same period last year.
August 13, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sutro Biopharma reported Q2 EPS of $(0.59), beating the $(0.79) estimate, and sales of $25.70M, surpassing the $21.02M estimate. This indicates strong financial performance and significant growth compared to the same period last year.
The better-than-expected EPS and sales figures indicate strong financial performance and growth, which is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100